Intellectual property

Jordan Freeman Joins Worlds Inc. Board of Directors

Retrieved on: 
Wednesday, March 20, 2024
Sony Interactive Entertainment, FlatOut, Commando, FlatOut 2, Living Books, WDDD, ZOOM, Freeman, Intellectual property, VS, Video game

Boston MA, March 20, 2024 (GLOBE NEWSWIRE) -- Worlds Inc. (OTCPK: WDDD) today announced that Jordan Freeman has joined its Board of Directors.

Key Points: 
  • Boston MA, March 20, 2024 (GLOBE NEWSWIRE) -- Worlds Inc. (OTCPK: WDDD) today announced that Jordan Freeman has joined its Board of Directors.
  • Mr. Freeman has a distinguished career in the video game industry and related licensing of intellectual property (IP).
  • Mr. Freeman was a mentee of the late Bernie Stolar, a Sony Computer Entertainment America co-founder, former Sega president and Worlds Inc. Board member.
  • In joining Worlds’ Board, I am looking forward to continuing and expanding the Worlds’ legacy, as it develops new technology and licensing opportunities that cross multiple generations of gamers.”

Spectral AI Announces Receipt of $1 Million of Financing for Spectral IP, Inc., its Intellectual Property Subsidiary Focused on the Broader Artificial Intelligence Ecosystem

Retrieved on: 
Tuesday, March 19, 2024
MDAI, Patent, Intellectual property, Artificial intelligence, IP, AI, Spectral, Ecosystem, Medical device

DALLAS, March 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has received a $1 million investment from an affiliate of its largest shareholder into its recently formed subsidiary Spectral IP, Inc. (“Spectral IP”).

Key Points: 
  • DALLAS, March 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has received a $1 million investment from an affiliate of its largest shareholder into its recently formed subsidiary Spectral IP, Inc. (“Spectral IP”).
  • Spectral IP will focus on advancing intellectual property (IP) in the broader AI ecosystem through acquisitions, strategic partnerships and collaborations with AI technology providers, healthcare institutions, and research organizations to accelerate innovation and expand market reach.
  • Wensheng Fan, Spectral AI’s Chief Innovation Strategist, said, “Medical Device companies are not only focusing on innovation to enhance their patent portfolios but are also making strategic investments in AI.
  • The integration of Artificial Intelligence is increasing in the medical device industry, but still lags other industries in its adoption.

Leading in health technology innovation: Philips one of the top patent applicants at European Patent Office

Retrieved on: 
Tuesday, March 19, 2024
Health, Informatics, PHG, Research, Software, AI, EPO, European Patent Convention, Patent, Intellectual property, Medtech, AEX, Medical device

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is one of the leading patent applicants at the European Patent Office (EPO).

Key Points: 
  • Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is one of the leading patent applicants at the European Patent Office (EPO).
  • Building on more than 130 years of innovation, Philips’ extensive global R&D programs and collaborations position the company at the forefront of health technology innovation.
  • With 607 MedTech patent applications in 2023, Philips is the second largest applicant in EPO's Patent Index 2023 in the field of medical technology.
  • In total, Philips contributed 1,299 patent applications across various domains, solidifying its standing among the top 10 patent filers overall.

FTI Consulting Expands Transfer Pricing Expertise in the United States with Addition of Cedric Bernardeau

Retrieved on: 
Monday, March 18, 2024
Organization, FCN, FTI Consulting, FTI, EY, Senior, Corporate finance, IP, Partner, Intellectual property, Cryptocurrency

Mr. Bernardeau, who is based in New York, has 30 years of experience with transfer pricing and supply chain/value chain operating model advisory matters.

Key Points: 
  • Mr. Bernardeau, who is based in New York, has 30 years of experience with transfer pricing and supply chain/value chain operating model advisory matters.
  • He has served both U.S. and non-U.S. multinational companies in analyzing their value chain as well as designing and supporting the implementation of new business models.
  • Commenting on his appointment, Mr. Bernardeau said, “When thinking about opportunities in any tax jurisdiction, it’s critical that organizations prioritize compliance and transparency.
  • FTI Consulting’s global platform provides the reach that companies need to help them manage international business challenges and opportunities.

DiagnaMed Strengthening Intellectual Property Support for CERVAI™ Brain Health AI Solution

Retrieved on: 
Thursday, March 14, 2024
Algorithm, IPON, Growth, SME, Intelligence, NRC, Education, Research, IRAP, Software, IP, National Research Council, Intellectual property, Creative industries

The Company has made significant progress in its AI algorithms and software and achieved certain research milestones that merit IP protection for commercializing CERVAI™ Brain Health AI solution.

Key Points: 
  • The Company has made significant progress in its AI algorithms and software and achieved certain research milestones that merit IP protection for commercializing CERVAI™ Brain Health AI solution.
  • Fabio Chianelli, Chairman and CEO of DiagnaMed, commented: “We have made significant technical and operating progress with CERVAI™, our novel brain health AI solution, and we are pleased to strengthen support of our intellectual property for commercialization with a potential $150,000 non-dilutive funding from IPON and IP Assist programs.
  • As part of our global commercialization plans for CERVAI™, we continue to invest in R&D and expand our intellectual property portfolio through patents, copyrights, trademarks and trade secrets.”
    With the IPON Partner Program, DiagnaMed can receive up to $35,000 in initial funding, with a further total grant of $100,000 for intellectual property protection and commercialization services.
  • DiagnaMed has completed IP Assist Level 1 with the IP Assist program and is eligible to receive up to $50,000 for expert IP services.

Fossil Group, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Wednesday, March 13, 2024
Failure, FOSL, Growth, Weakness, Terrorism, Operating cost, Information, Security (finance), Loss, TAG, Annual report, GAAP, Rationalization, Interim, Inventory, Fossil Group, Jewellery, Intellectual property, Regulation, MICHAEL, Video game

RICHARDSON, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the fourth quarter and fiscal year ended December 30, 2023. Separately, the Company also announced today that Kosta N. Kartsotis has stepped down as Chief Executive Officer and Jeffrey N. Boyer, Chief Operating Officer, has been appointed Interim CEO, effective immediately.

Key Points: 
  • RICHARDSON, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the fourth quarter and fiscal year ended December 30, 2023.
  • As a percentage of net sales, operating expenses were 53.3% in the fourth quarter of 2023 compared to 46.9% in the prior year fourth quarter.
  • Operating margin was (5.7)% in the fourth quarter of 2023 compared to 0.3% in the prior year fourth quarter.
  • Adjusted operating margin was (2.0)% in the fourth quarter of 2023 compared to 0.6% in the prior year fourth quarter.

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Retrieved on: 
Wednesday, March 13, 2024
CD4, PDSB, Infection, Patent, Influenza, Research, Virus, Biotechnology, Antibody, Intellectual property, Use, Viral, Vaccine

PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell-activating platforms, today announced the publication of preclinical research and a patent granted by the United States Patent and Trademark Office (USPTO) that strengthen the foundation of the Company’s infectious disease vaccine platform Infectimune®.

Key Points: 
  • The research concluded that Infectimune® is a leading candidate for use in the next generation of preventive vaccines that may provide more effective and broader protection than current vaccines allow.
  • Infectimune® is being used in PDS0202, the Company’s universal influenza vaccine intended to provide broad protection against multiple flu strains.
  • The patent protects compositions containing the Infectimune® platform and influenza antigens and methods of using the Infectimune® platform with pathogenic antigens generally.
  • “Possessing multiple layers of intellectual property for our assets is an important value driver for PDS Biotech and is a key component of our business strategy.”

Music Licensing, Inc. (OTC: SONG) Initiates Strategic Stock Restructuring and Highlights Key Achievements

Retrieved on: 
Tuesday, March 12, 2024
OTC Markets Group, Common stock, Acquisition, XXXTENTACION, Listerine, OTC, Music licensing, Intellectual property, Music

In line with our steadfast commitment to optimizing our capital structure, Music Licensing, Inc. has embarked on a strategic stock consolidation program, employing a 500,000:1 share consolidation ratio.

Key Points: 
  • In line with our steadfast commitment to optimizing our capital structure, Music Licensing, Inc. has embarked on a strategic stock consolidation program, employing a 500,000:1 share consolidation ratio.
  • This strategic maneuver is engineered to significantly reduce the outstanding number of Common Stock shares to below 30,000 shares, exceeding our initial projections.
  • Subsequent to this consolidation, Music Licensing, Inc. (OTC: SONG) will expedite the implementation and finalization of the long-anticipated Common Stock Buy-Back program, initially unveiled in 2023.
  • In addition to these achievements, Music Licensing, Inc. reported exceptional financial performance, with stellar earnings announced on February 26, 2024.

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

Retrieved on: 
Tuesday, March 12, 2024
Psilocybin, Hospice, Letter, Growth, Newcourt, Psychotherapy, Mental health, Research, Fungus, Contract research organization, Adjustment disorder, NCE, Phase, Optimism, Intellectual property, Patent, Therapy, Medicine, PBM, Pharmaceutical industry

Our merger with Newcourt and subsequent listing on Nasdaq confers numerous benefits to our company.

Key Points: 
  • Our merger with Newcourt and subsequent listing on Nasdaq confers numerous benefits to our company.
  • While other companies are exploring synthetic psilocybin, Psyence is the world’s first Nasdaq traded biopharmaceutical company researching a nature-derived (non-synthetic) psilocybin candidate.
  • Furthermore, Psyence is the only publicly traded company to research a non-synthetic psilocybin candidate to treat Adjustment Disorder in the context of Palliative Care.
  • To reflect this exciting new chapter in our company’s evolution, we have created a new investor presentation, which can be found here .

United States 3D Printing Markets, Competition Forecast & Opportunities, 2028F: Significant Expansion Driven by Technological Innovations and Applications in Aerospace and Healthcare - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Automotive Manufacturing, Aerospace, Manufacturing, Machinery, Chemicals, Plastics, Attention, Growth, Surgeon, Health, Science, Printing, Biomaterial, Partnership, Intellectual property, Anatomy, COVID-19, Quality control, Research, Boeing, 3D, NASA, Investment, Ecosystem, Safety, 3D Systems, SpaceX, Stratasys, HP, 3D printing

The "United States 3D Printing Market, By Region, By Competition Forecast & Opportunities, 2018-2028F" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States 3D Printing Market, By Region, By Competition Forecast & Opportunities, 2018-2028F" report has been added to ResearchAndMarkets.com's offering.
  • The United States 3D printing market has emerged as a dynamic and transformative force in the global manufacturing landscape.
  • One of the primary drivers of the 3D printing market in the United States is the continuous innovation in 3D printing technologies.
  • American companies and research institutions have been at the forefront of developing cutting-edge 3D printing techniques, materials, and processes.